Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
5
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
5
×
indiana blog main
5
×
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
gene therapy
novartis
abbvie
alzheimer's disease
amgen
bristol-myers squibb
cancer immunotherapy
clinical trials
deals
eli lilly
fda
What
bio
5
×
roundup
crispr
days
drug
new
news
remains
acquisitions
albert
alliance
allogene
approval
august
biggest
biogen’s
biopharmaceutical
biotech
bourla
bristol
busy
buy
calls
cancer
ceo
changing
color
companies
company
convo
decisions
devices
diversity
drugs
earlier
failures
fda
future
growing
hot
Language
unset
unknown
Current search:
glaxosmithkline
×
bio
×
biogen
×
" indiana blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More